Iovance appoints Wendy Dixon to board; retains chairman Dukes after failed re-election

IOVANCE BIOTHERAPEUTICS, INC.

Appointed Wendy Dixon, Ph.D. to board effective June 10, 2022; granted RSU valued at $425,000 (8.30/sh).
Chairman Iain Dukes received more withheld votes than for votes at annual meeting; board rejected his conditional resignation.
Dukes' non-independence due to prior consulting agreement expires Dec 2022; board cited valuable contributions.
Stockholders approved increase in 2018 Equity Plan from 14M to 20.7M shares (6.7M new shares).
Other proposals: executive compensation (advisory) and auditor ratification passed.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wendy Dixon

Director

IOVA · IOVANCE BIOTHERAPEUTICS, INC.

Effective: 2022-06-10
Filed: June 13, 2022, 7:59 PM ET

appointed Wendy Dixon, Ph.D., as a director and new member of the Board, effective June 10, 2022, to fill such newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy Dixon was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Wendy Dixon, Ph.D., as a director and new member of the Board, effective June 10, 2022, to fill such newly created vacancy.

View on SEC.gov

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-070604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.